A NEW APPROACH TO THE DIFFERENTIAL DIAGNOSIS OF NON-ALCOHOLIC AND ALCOHOLIC LIVER DISEASE
Main Article Content
Abstract
Differential diagnosis of non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) at the stage of steatosis presents significant difficulties in the practice of a primary care physician. Low-symptomatic manifestations and non-specific symptoms at an early stage of NAFLD and ALD development often complicate timely diagnosis, which is fraught with the progression of these common liver diseases. In the NAFLD pathogenesis lies a violation of lipid metabolism, which has a multifactorial character, including a disturbance of the synthesis of the adipose tissue hormone - leptin. Whereas in the ALD development, the effect on hepatocytes of ethanol and its metabolite, acetaldehyde, is of leading importance. The differences in the NAFLD and ALD etiopathogenesis gave rise to the study of the content of adipose tissue hormone in blood serum in the patients of the two groups compared.
The aim is to study the level of serum leptin as an additional differential diagnostic criterion for non-alcoholic fatty liver disease and alcoholic liver disease.
The subject of the study is the content of serum leptin in patients with NAFLD and ALD.
Research methods. A comparative analysis of the serum leptin level in 108 patients with NAFLD and 80 patients with ALD was carried out, taking into account the body mass index and gender differences.
Results. Significant differences in the serum leptin content in patients with NAFLD and ALD were revealed. The results obtained can serve as an additional differential diagnostic criterion between NAFLD and ALD at early stages.
Conclusion. The obtained results of the study confirm the participation of the adipose tissue hormone leptin in the NAFLD development, regardless of gender differences, and can serve as a differential diagnostic criterion for NAFLD and ALD in the outpatient practice of a general practitioner. For a deeper understanding of the mechanism of the NAFLD development, it is necessary to study the polymorphism of the leptin receptor gene both in the patients with NAFLD and in the patients with ALD.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Ametov AS. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: practical recommendations for endocrinologists. Farmateka. 2013; (5): 58-67. Russian (Аметов А.С. Сахарный диабет 2 типа и неалкогольная жировая болезнь печени: практические рекомендации для эндокринологов //Фарматека. 2013. № 5. С. 58-67)
Bagmen AP, Korenblaitt K, Klein S. Nutrition and the liver. In: Schiff ER, Maddrey WC, Sorrell MF; transl. from the English Ivashkin VT, Bueverov AO, Maevskaya MV. Fundamentals of Hepatology. Moscow: GEOTAR-Media; 2011: 551-592. Russian (Багмен А.П., Коренблайтт К., Клейн С. Питание и печень //Введение в гепатологию /Шифф Ю.Р., Мэддрей У.С., Соррел М.Ф.; пер. с англ. под ред. В.Т. Ивашкина, А.О. Буеверова, М.В. Маевской. М.: ГЭОТАР-Медиа, 2011. С. 551-592)
Bogomolov PO, Shulpekova YuO. Liver steatosis and non-alcoholic steatohepatitis. In: Ivashkin VT. Diseases of the liver and biliary tract. 2-nd ed. Moscow: M-Vesti; 2005: 205-216. Russian (Богомолов П.О., Шульпекова Ю.О. Стеатоз печени и неалкогольный стеатогепатит //Ивашкин В.Т. Болезни печени и желчевыводящих путей. 2-е изд. М.: М-Вести. 2005. С. 205-216)
Bubnova MG. Obesity: causes and mechanisms of weight gain, approaches to correction. Consilium Medicum. 2005; 7(5): 23-26. Russian (Бубнова М.Г. Ожирение: причины и механизмы нарастания массы тела, подходы к коррекции //Consilium Medicum. 2005. Т. 7, № 5. С. 23-26)
Bueverov AO, Bogomolov PO, Maevskaya MV. Pathogenetic treatment of non-alcoholic steatohepatitis: rationale, efficacy, safety. Terapevticheskiy arkhiv. 2007; (8): 1-4. Russian (Буеверов А.О., Богомолов П.О., Маевская М.В. Патогенетическое лечение неалкогольного стеатогепатита: обоснование, эффективность, безопасность //Терапевтический архив. 2007. № 8. С. 1-4)
Kozlov VK, Radchenko VG, Anikonova LI, Budai AP, Mekhtieva OA, Polyakova VV, et al. Questions of strategy and tactics for the prevention of pre-nosological conditions and diseases of internal organs. M.: 4TE Art; 2011. Russian (Козлов В.К., Радченко В.Г., Аниконова Л.И., Будай А.П., Мехтиева О.А., Полякова В.В., и др. Вопросы стратегии и тактики профилактики донозологических состояний и заболеваний внутренних органов. М.: 4ТЕ Арт, 2011)
Gerok V, Blyum KhE. Diseases of the liver and biliary system. M.: MEDpress-inform, 2009. Russian (Герок В., Блюм Х.Е. Заболевания печени и желчевыделительной системы. М.: МЕДпресс-информ, 2009)
Glants S. Medico-biological statistics. M.: Practice, 1998. Russian (Гланц С. Медико-биологическая статистика. М.: Практика, 1998)
Dedov II, Romantseva TI. Central and peripheral mechanisms of body mass regulation. In: Dedov II., ed. Morbid obesity. M., 2014: 17-56. Russian (Дедов И.И., Романцева Т.И. Центральные и периферические механизмы регуляции массы тела //Морбидное ожирение /под ред. И.И. Дедова. М., 2014. С. 17-56)
Drapkina OM, Ivashkin VT. Epidemiologic features of non-alcoholic fatty liver disease in Russia (Results of open multicenter prospective observational study DIREG L 01903). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014; (4): 32-38. Russian (Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L01903) //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014. № 4. С. 32-38)
Zvenigorodskaya LA, Kucherenko TV. Types of eating behavior and hormones of eating behavior in patients with metabolic syndrome. Experimental & clinical gastroenterology. 2007; (1): 24-7. Russian (Звенигородская Л.А., Кучеренко Т.В. Типы пищевого поведения и гормоны пищевого поведения у больных с метаболическим синдромом //Экспериментальная и клиническая гастроэнтерология. 2007. № 1. С. 24-27)
Diagnosis and treatment of non-alcoholic fatty liver disease. Ed. Ivashkin VT. M., 2015. Russian (Диагностика и лечение неалкогольной жировой болезни печени /под ред. В.Т. Ивашкина. М., 2015)
Kytikova OYu, Novgorodtseva TP, Denisenko YuK, Kovalevsky DA. Metabolic and genetic determinants of lipid metabolism disruption in non-alcoholic fatty liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020; 30(2): 15-25. Russian (Кытикова О.Ю., Новгородцева Т.П., Денисенко Ю.К., Ковалевский Д.А. Метаболические и генетические детерминанты нарушения липидного обмена при неалкогольной жировой болезни печени //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Т. 30, № 2. С.15-25.) https://doi.org/10.22416/1382-4376-2020-30-2-15-25
Livzan MA, Kolbina MV, Matoshina IV, Zherebilov VV, Nikolaev NA, Khrapova IA, Loseva YuP. Hormones adipose tissue and non-alcoholic fatty liver disease at metabolic syndrome. Dnevnik kazanskoy meditsinskoy shkoly. 2014; (1): 44-8. Russian (Ливзан М.А., Колбина М.В., Матошина И.В., Жеребилов В.В., Николаев Н.А., Храпова И.А., Лосева Ю.П. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме //Дневник казанской медицинской школы. 2014. № 1. С. 44-48)
Mantsoros KhS. Modern ideas about the role of leptin in the development of obesity and related human diseases. International Journal of Medical Practice. 2000; (9): 57-67. Russian (Манцорос Х.С. Современные представления о роли лептина в развитии ожирения и связанных с ним заболеваний человека //Международный журнал медицинской практики. 2000. № 9. С. 57-67)
Plyusnin SV, Ivashkin KV, Bobrov AN, Belyakin SA, Plyusnina IV. Alcohol-induced liver disease: primary and secondary prevention. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; (3): 42-48. Russian (Плюснин С.В., Ивашкин К.В., Бобров А.Н., Белякин С.А., Плюснина И.В. Алкогольная болезнь печени: первичная и вторичная профилактика //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015. № 3. С. 42-48)
Boytsov SA, Chuchalin AG, Arutyunov GP, Bilichenko TN, Bubnova MG, Ipatov PV et al. Prevention of chronic non-communicable diseases. Recommendations. M., 2013. Russian (Бойцов С.А., Чучалин А.Г., Арутюнов Г.П., Биличенко Т.Н., Бубнова М.Г., Ипатов П.В. и др. Профилактика хронических неинфекционных заболеваний: рекомендации. М., 2013)
Tkachenko EV, Varvanina GG. Gastrointestinal hormones in clinical gastroenterology. Terapevticheskiy arkhiv. 2009; (2): 87-90. Russian (Ткаченко Е.В., Варванина Г.Г. Гастроинтестинальные гормоны в клинической гастроэнтерологии //Терапевтический архив. 2009. № 2. С. 87-90)
Fletcher R, Fletcher S, Wagner E. Clinical epidemiology. Fundamentals of evidence-based medicine. M.: Media Sphere, 1998. Russian (Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. М.: Медиа Сфера, 1998)
Adams LA, Lymp J.E., St. Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The nature history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1): 113-121. DOI: 10.1053/j.gastro.2005.04.014
Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5): 1705-1725. DOI: 10.1053/gast.2002.36572
Ben AS, Kallel A, Sediri Y, Ftouhi B, Feki M, Slimene H, et al. LEPR p.Q223R Polymorphism influences plasma leptin levels and body mass index in Tunisian obese patients. Arch Med Res. 2009; 40(3): 186-190. DOI: 10.1016/j.arcmed.2009.02.008
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142(7): 1592-1609
Dixon YB, Bhathal DS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121(1): 91-100. DOI: 10.1053/gast.2001.25540
Farooqi IS, O’Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr. 2009; 89: 980-984
Friedman JM. Leptin at 14 y of age: an ongoing story. Am J Clin Nutr. 2009; 89(3): 980S-984S. DOI: 10.3945/ajcn.2008.26788C
Friedman JM. Leptin, leptin receptors, and the control of body weight. Eur J Med Res. 1997; 2(1): 7-13
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997; 387(6636): 903-908. DOI: 10.1038/43185
Mori S, Yamasaki T, Sakaida I, Takami T, Sakaguchi E, Kimura T, et al. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol. 2004, 39(4): 391-396
Pessayre D, Mansouri A, Fromenty B. Non-alcoholic steatohepatitis: potential causes and pathogenic mechanisms. In: Hepatology 2000. Falk symposium 117. Boston: Kluwer Academic Publishers, 2000: 57-76
Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI. A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet. 2001; 108(3): 233-236. DOI: 10.1007/s004390100468
Woods AJ, Stock MJ. Leptin activation in hypothalamus. Nature. 1996; 381: 745